A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite
Current prophylaxis for infected tick bites consists of personal protective measures directed towards ticks. This study compared the efficacy of a single oral dose of doxycycline with that of a single injection of sustained-release doxycycline in a model of Lyme borreliosis and Anaplasma phagocytophilum infection. Dosages of doxycycline were equilibrated based on previously determined peak plasma levels in mice [oral, 2.4 μg (ml plasma)−1; sustained release, 1.9 μg (ml plasma)−1] determined 8 h after inoculation. In challenge experiments where five Borrelia burgdorferi-infected and five A. phagocytophilum-infected nymphs were used per mouse, only 20 and 30 % of mice were protected from B. burgdorferi and A. phagocytophilum infection, respectively, using oral doxycycline. In contrast, 100 % of mice receiving sustained-release doxycycline were protected from A. phagocytophilum infection, as indicated by real-time PCR of blood samples, quantitative PCR and culture isolation of spleen samples, and protected against B. burgdorferi infection as demonstrated by culture of ear, heart and bladder. Although 15–40 copies of A. phagocytophilum could be amplified from the spleens of mice treated with sustained-release doxycycline, no viable A. phagocytophilum from these spleens could be cultured in HL-60 cells. In contrast, 7/10 mice receiving oral doxycycline were PCR- and culture-positive for A. phagocytophilum, with copy numbers ranging from 800 to 10 000 within the spleen, as determined by quantitative PCR. Other correlates with A. phagocytophilum infection included a significant difference in spleen mass (mean of 110 mg for sustained-release treatment versus a mean of 230 mg for oral treatment) and the number of splenic lymphoid nodules (mean of 8 for sustained-release treatment versus mean of 12.5 for oral doxycycline) as determined by histopathology. These studies indicate that a single injection of a sustained-release formulation antibiotic may offer a viable prophylactic treatment option for multiple infectious agents in patients presenting with tick bites.
Aguero-RosenfeldM. E.,
DonnarummaL.,
ZentmaierL.,
JacobJ.,
FreyM.,
NotoR.,
CarbonaroC. A.,
WormserG. P.2002; Seroprevalence of antibodies that react with Anaplasma phagocytophila , the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol 40:2612–2625[CrossRef]
DuffyJ.,
PittlekowM. R.,
KolbertC. P.,
RutledgeB. J.,
PersingD. H.1997; Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis. Lancet 349:399
JohnsonR. C.,
KodnerC. B.,
JurkovichP. J.,
CollinsJ. J.1990; Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 34:2133–2136[CrossRef]
MassungR. F.,
ZeidnerN. S.,
DolanM. C.,
RoelligD.,
GatitzschE.,
TroughtonD. R.,
LevinM. L.2005; Prophylactic use of sustained-release doxycycline blocks tick-transmitted infection by Anaplasma phagocytophilum in a murine model. Ann N Y Acad Sci 1063:436–438[CrossRef]
MatschkeC.,
IseleU.,
HoogevetP. V.,
FahrA.2002; Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release 85:1–15[CrossRef]
MaurinM.,
BakkenJ. S.,
DumlerJ. S.2003; Antibiotic susceptibilities of Anaplasma ( Ehrlichia ) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 47:413–415[CrossRef]
NadelmanR. B.,
HorowitzH. W.,
HsiehT. C.,
WuJ. M.,
Aguero-RosenfeldM. E.,
SchwartzI.,
NowakowskiJ.,
VardeS.,
WormserG. P.1997; Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 337:27–30[CrossRef]
NadelmanR. B.,
NowakowskiJ.,
FishD.,
FalcoR. C.,
FreemanK.,
McKennaD.,
WelchP.,
MarcusR.,
Aguero-RosenfeldM. E.other authors2001; Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 345:79–84[CrossRef]
PancholiP.,
KolbertC. P.,
MitchellP. D.,
ReedK. D.,
DumlerJ. S.,
BakkenJ. S.,
TelfordS. R.III,
PersingD. H.1995; Ixodes dammini as a potential vector of human granulocytic ehrlichiosis. J Infect Dis 172:1007–1012[CrossRef]
PiesmanJ.1993; Standard system for infecting ticks (Acari: Ixodidae) with the Lyme disease spirochete Borrelia burgdorferi
. J Med Entomol 30:199–203[CrossRef]
StaffordK. C.,
MassungR. F.,
MagnarelliL. A.,
IjdoJ. W.,
AndersonJ. F.1999; Infection with agents of human granulocytic ehrlichiosis, Lyme disease, and babesiosis in wild white-footed mice in Connecticut. J Clin Microbiol 37:2887–2892
WormserG. P.,
RamanathanR.,
NowakowskJ.,
McKennaD.,
HolmgrenD.,
VisintainerP.,
DornbushR.,
SinghB.,
NadelmanR. B.2003; Duration of antibiotic therapy for early Lyme disease. Ann Intern Med 138:697–704[CrossRef]
ZeidnerN. S.,
BrandtK. S.,
DadeyE.,
DolanM. C.,
HappC.,
PiesmanJ.2004a; Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. Antimicrob Agents Chemother 48:2697–2699[CrossRef]
ZeidnerN. S.,
CarterL. G.,
MonteneiriJ. A.,
PetersenJ. M.,
SchrieferM.,
GageK. L.,
HallG.,
ChuM. C.2004b; An outbreak of Francisella tularensis in captive prairie dogs: an immunohistochemical analysis. J Vet Diagn Invest 16:150–152[CrossRef]
A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite